Jaime Schneider, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, provides an overview of the latest developments in treating ALK-mutated lung cancer. Updates in the CROWN trial (NCT03052608) of lorlatinib have demonstrated the potential of novel ALK inhibitors in the first line setting. Whilst on-target resistance mechanisms are well known, Dr Schneider additionally highlights the need to focus research efforts on other bypass mechanisms. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
